Annals of Oncology Advance Access originally published online on May 23, 2008
Annals of Oncology 2008 19(9):1566-1572; doi:10.1093/annonc/mdn180
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
breast cancer |
Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database
1 Department of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin 4
2 UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin 4, Ireland
* Correspondence to: Prof M. J. Duffy, Phd, FRCP Nuclear Medicine Laboratory, St Vincent's University Hospital, Dublin 4, Ireland. Tel: +353-1-2094378; Fax: +353-1-2696018; E-mail: michael.j.duffy{at}ucd.ie
Traditionally, matrix metalloproteinases (MMPs) have been implicated in cancer invasion and metastasis. Because of their role in these processes, several MMPs have been investigated for potential prognostic value as well as targets for antimetastatic therapy. In this investigation, we used a publically available database to relate messenger RNA expression levels for 17 different MMPs to tumor characteristics and outcome in patients with breast cancer. Of the MMPs investigated, only MMP-1 was significantly increased in tumors >2 cm in size compared with those 
2 cm while MMP-1, -9, -12 and -15 were significantly elevated in high-grade compared with low-grade tumors. Only MMP-10 was higher in lymph node-positive compared with lymph node-negative cancers. Using univariate analysis, high expressions of MMP-1, -9, -12, -14 and -15 were associated with poor overall survival. Of these five, only MMP-14 predicted outcome independent of tumor size, tumor grade and lymph node status. None of the MMPs investigated were associated with good outcome. We conclude that only a minority of MMPs, i.e. MMP-1, -9, -12, -14 and -15, are associated with adverse outcome in patients with breast cancer. These MMPs are likely to be involved in mediating breast cancer progression and may thus be good targets for designing specific MMP inhibitors for the treatment of breast cancer.
Key words: breast cancer and prognosis, metalloproteinases
Received for publication January 17, 2008. Revision received March 28, 2008. Accepted for publication March 31, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. E. Wilkins-Port, Q. Ye, J. E. Mazurkiewicz, and P. J. Higgins TGF-{beta}1 + EGF-Initiated Invasive Potential in Transformed Human Keratinocytes Is Coupled to a Plasmin/MMP-10/MMP-1-Dependent Collagen Remodeling Axis: Role for PAI-1 Cancer Res., May 1, 2009; 69(9): 4081 - 4091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sabeh, R. Shimizu-Hirota, and S. J. Weiss Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited J. Cell Biol., April 6, 2009; 185(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|